ESC 365 - What is the evidence and which aldosterone antagonist should a patient with HFmrEF receive?

Open Access

What is the evidence and which aldosterone antagonist should a patient with HFmrEF receive?

Session: Current pharmacological treatment of heart failure with mid-range ejection fraction

Topic: Chronic Heart Failure

Speaker: Professor F. Martinez (Cordoba, AR)

Event: Heart Failure 2021 Online Congress

Congress Session

About the speaker

Professor Felipe Martinez

State University of Cordoba, Cordoba (Argentina)

2 presentations

0 follower

3 more presentations in this session

What is the evidence and which beta-blocker should a patient with HFmrEF receive?

Speaker: Professor A. Coats (Coventry, GB)

What other pharmacological treatments should a patient with HFmrEF receive?

Speaker: Professor L. Lund (Stockholm, SE)

Current pharmacological treatment of heart failure with mid-range ejection fraction - discussion.

Access the full session

Current pharmacological treatment of heart failure with mid-range ejection fraction

Speakers: Professor F. Martinez, Professor A. Coats, Professor L. Lund

About the event

Heart Failure 2021 Online Congress

29 June - 1 July 2021

Sessions Presentations

Congress

Related content

Open Access

Pathophysiology and evolving definition of cardiogenic shock.

19 March 2022

Open Access

Medical treatment depends on etiology!

18 March 2022

Open Access

Major arterial and venous thromboembolic complications in patients with covid-19

27 August 2021

This platform is supported by